Rationale, design, and baseline results of the Pravastatin-to- Simvastatin Conversion Lipid Optimization Program (PSCOP)

American Journal of Health-System Pharmacy

Volumn 56, Issue 11, 1999, Pages 1107-1113

  Ito, Matthew K ^a,b   Stolley, Stephen N ^c   Morreale, Anthony P ^c,d   Lin, Jennifer C ^d   Marcus, David B ^c  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c VASDHS   (United States)

^d UCHSC

Author keywords

Antilipemic agents; Coronary disease; Hypercholesterolemia; Pravastatin; Protocols; Simvastatin; Substitution

Indexed keywords

GEMFIBROZIL; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG CHOICE; DRUG EFFICACY; DRUG UTILIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0033152652     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.11.1107     Document Type: Article

References (17)

1. American Heart Association. Cardiovascular disease statistics. http://www.amhrt.org/Heart_and_Stroke_A_Z_Guide/ cvds.html (accessed 1999 May 3).
2. Pedersen TR, Kjekshus J, Berg K et al., for the Scandinavian Simvastatin Survival Study Group. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation. 1996; 93:1796-802.
3. National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults II. Circulation. 1994; 93:1329-445.
4. Pitt B, Ellis SG, Mancini GBJ et al., for the PLAC I Investigators. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol. 1993; 72:31-5.
5. Jukema JW, Bruschke AVG, van Boerma AJ et al., for the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995; 91:2528-40.
6. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994; 344:633-8.
7. Shepherd J, Cobbe SM, Ford I et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-7.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-9.
9. Sacks FM, Pfeffer MA, Moye LA et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-9.
10. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996; 100:605-10.
11. O'Conner PJ, Rush WA, Trence DL. Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization. J Fam Pract. 1997; 44:462-7.
12. Pearson TA, Laurora IM. Treatment success in patient subgroups in the Lipid Treatment Assessment Project (L-TAP). Circulation. 1997; 96:166. Abstract.
13. Consolidated mail outpatient pharmacy (CMOP) user manual. Department of Veterans Affairs: VISTA Software Development. Clinical Ancillary Product Line (version 2.0); 1997 Apr.
14. Ito MK. Effects of extensive and poor gastrointestinal metabolism on the pharmacodynamics of pravastatin. J Clin Pharmacol. 1998; 38:331-6.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge. Clin Chem. 1972; 18:499-502.
16. Gill MA, Chenella FC, Ito MK et al. A cost comparison of clindamycin and aztreonam versus clindamycin and gentamicin in perforated or gangrenous appendicitis. Curr Ther Res. 1987; 42:680-9.
17. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998; 279:1615-22.